MicroCHIPS granted new patent for implantable device

Drug delivery device developer MicroCHIPS, based in Waltham, MA, has been granted a U.S. Patent that, the company says, "provides broad coverage for the design and fabrication of reservoir-based medical devices used for implantable drug delivery systems." The patent, "Method of Controlled Drug Delivery from Implant Device" goes hand-in-hand with previously granted patents to help solidify the company's intellectual property in this space, the company said in a release.

"The granting of this patent provides the fundamental building blocks for programmable medical drug delivery implants to address various diseases such as diabetes, osteoporosis, heart disease and cancer," MIT researcher Robert Langer said in a release.

MicroCHIPS' technology originated at MIT based on research by Langer, Michael Cima and cofounder John Santini. The technology is currently part of a clinical trial to treat osteoporosis in women. The trial is evaluating precise delivery of human parathyroid hormone from a programmable, wireless implanted device, the release said.

- read the MicroCHIPS release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.